ITHACA, N.Y. – March 24, 2014 - Rheonix, Inc., a developer of fully automated molecular testing solutions, announced today that it has been invited to exhibit at “The Future of In-Vitro Diagnostics.” The exclusive conference, held April 10, 2014 in Menlo Park/Palo Alto, CA, is hosted by Siemens Venture Capital, the investment arm of Siemens, and Siemens Healthcare.
The fifth annual conference brings together over 100 CEOs and CTOs, investors, key… Read More »
ITHACA, N.Y. — Rheonix Inc., a developer of fully automated molecular diagnostics solutions, has been granted six additional patents for its core microfluidic device, the Chemistry and Reagent Device, or CARD® . One patent was issued Feb. 11, while the other five have been allowed but not yet issued.
The Rheonix CARD is a disposable cartridge the size of a credit card that runs multiple samples simultaneously without user intervention. Once… Read More »
ITHACA, N.Y. — Rheonix, Inc., a developer of fully automated molecular testing solutions, has created a channel-free microfluidic device, the Rheonix Smart FilmCARD™. The Smart FilmCARD would be the first microfluidic device in the diagnostics industry with no channels included in its design, a breakthrough that will significantly decrease the research, development and production costs of microfluidic solutions and allow sophisticated diagnostic tests to become more widely available. The Smart… Read More »
ITHACA, N.Y. — Rheonix Inc., a developer of fully automated molecular testing solutions, has established the Rheonix Innovation Center to allow the company to continue to develop core technology within its expansive intellectual property portfolio. The center is adjacent to the company’s new headquarters in Ithaca, N.Y.
Employees within the center will be tasked with applying Rheonix’s technical capabilities to solving molecular testing challenges outside the traditional scope of automated molecular… Read More »
ITHACA, N.Y. — Rheonix Inc., a developer of fully automated molecular testing solutions, raised $14 million in a combination of debt and equity investments to complete a manufacturing build out and launch its first commercial product. The funds will be used to expand the company’s physical operations to produce consumables and systems to fulfill Rheonix’s joint development agreement with Life Technologies Corp. and for the commercialization of its first clinical,… Read More »
With $14 MILLION in debt and equity financing in hand, molecular diagnostics firm Rheonix is planning to expand both its physical footprint and molecular testing product portfolio in the coming year, company president Tony Eisenhut said this week.
First, Rheonix is already in the process of building out new manufacturing facilities just down the street from its current Ithaca, NY, headquarters, primarily to enable it to produce consumables and systems to… Read More »
ITHACA, N.Y. — Genetic testing laboratories currently face constraints such as complex sample preparation, complicated workflow and long waits for test results. Molecular diagnostics executive Richard Montagna, Ph.D., vice president for scientific affairs for Rheonix Inc., an Ithaca-based developer of an automated molecular testing platform, will present ways to overcome some of these challenges and provide cost-effective molecular diagnostics for personalized medicine at an international conference later this month.
“We are… Read More »
ITHACA, N.Y. – Rheonix Inc., a developer of fully automated molecular testing solutions, will address the need for access to critical advanced molecular testing, labor shortages that limit the availability of testing, and other obstacles laboratories face in adoption of this technology at the Association for Molecular Pathology (AMP) 2013 Annual Meeting in Phoenix, Ariz., Nov. 14-16.
Rheonix will display its Chemical and Reagent Device (CARD) and EncompassMDx™ molecular testing platform.… Read More »
ITHACA, N.Y. — Rheonix, Inc., a developer of fully automated molecular testing solutions, has received a $500,000 Small Business Innovation Research (SBIR) Phase IIB grant from the National Science Foundation (NSF). The funding adds to the $650,000 the company previously received in NSF SBIR Phase I, Phase IB and Phase II funding for this project and will allow Rheonix to expand the capabilities of its pathogen detection system from the… Read More »
The development of multiplex companion diagnostics is driven by the need to understand efficacy and safety at both the molecular and phenotypic levels. In the future, personalized therapeutic regimens will be tailored to each patient’s genomic, transcriptomic, and epigenomic profiles to optimize individual outcomes.
For personalized (or precision) medicine to become a sustaining reality, all stakeholders—patients, healthcare professionals, drug development companies, regulatory agencies and payers—must work together.
Advancing multiplex companion diagnostics technology… Read More »